CHILDHOOD OSTEOPOROSIS AND PRESENTATION OF TWO CASES WITH OSTEOGENESIS IMPERFECTA TYPE V

被引:2
|
作者
Bratanic, Nina [1 ]
Dzodan, Bojana [1 ]
Trebusak Podkrajsek, Katarina [2 ,4 ]
Bertok, Sara [1 ]
Ostanek, Barbara [3 ]
Marc, Janja [3 ]
Battelino, Tadej [1 ,4 ]
Avbelj Stefanija, Magdalena [1 ]
机构
[1] Univ Childrens Hosp, Dept Pediat Endocrinol Diabet & Metab Dis, Ljubljana 1000, Slovenia
[2] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Unit Special Lab Diagnost, Ljubljana 1000, Slovenia
[3] Univ Ljubljana, Fac Farmacy, Ljubljana 1000, Slovenia
[4] Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia
来源
ZDRAVSTVENO VARSTVO | 2015年 / 54卷 / 02期
关键词
bone mineral density; hypertrophic callus; IFITM5; gene; bisphosphonates; HYPERPLASTIC CALLUS FORMATION; BISPHOSPHONATE THERAPY; PHENOTYPIC VARIABILITY; FOLLOW-UP; MUTATION; CHILDREN; FRACTURES; POLYMORPHISM; ADOLESCENTS; PAMIDRONATE;
D O I
10.1515/sjph-2015-0018
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction. Osteogenesis imperfecta (OI) is etiologically heterogeneous disorder characterized by childhood osteoporosis. A subtype OI type V is caused by the same c.-14C>T mutation in the IFITM5 gene. Nevertheless, there is a marked interindividual phenotypic variability in clinical presentation; however, response to bisphosphonates is reported to be good. Methods. Two individuals with OI type V had multiple recurrent fractures with hypertrophic calluses, scoliosis and ossifications of the forearm interosseous membranes. Sequencing of IFITM5, genotyping of variants rs2297480 in farnesyl diphosphate synthase gene (FDPS), and rs3840452 in geranylgeranyl diphosphate synthase 1 gene (GGPS1), both involved in bisphosphonate metabolism, was performed. Results. In patient 1 BMD reached normal values during bisphosphonate treatment and remained normal four years after the treatment discontinuation. In patient 2 no increase in BMD after five years of bisphosphonate treatment was observed and callus formation continued. The c.-14C>T IFITM5 mutation in heterozygous state was detected in both individuals. Additionally, both patients carried FDPS variant rs2297480 in homozygous state, and were heterozygous for GGPS 1 variant rs3840452. Conclusions. The paper presents a short overview of childhood osteoporosis with a special emphasis on OI type V by presenting two cases. Both OI type V patients had identical disease-causing mutation, but marked interindividual phenotypic variability. The striking failure in response to bisphosphonate treatment in one of the patients could not be explained by the variants in genes involved in bisphosphonate metabolism.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [41] First use of the RANKL antibody denosumab in Osteogenesis Imperfecta Type VI
    Semler, O.
    Netzer, C.
    Hoyer-Kuhn, H.
    Becker, J.
    Eysel, P.
    Schoenau, E.
    JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2012, 12 (03) : 183 - 188
  • [42] Specific Characteristic of Hyperplastic Callus in a Larger Cohort of Osteogenesis Imperfecta Type V
    Wen-bin Zheng
    Jing Hu
    Jia Zhang
    Zheng Yang
    Ou Wang
    Yan Jiang
    Wei-bo Xia
    Xiao-ping Xing
    Wei Yu
    Mei Li
    Calcified Tissue International, 2022, 110 : 451 - 463
  • [43] Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
    Heike Hoyer-Kuhn
    Christian Netzer
    Friederike Koerber
    Eckhard Schoenau
    Oliver Semler
    Orphanet Journal of Rare Diseases, 9
  • [44] Physical activity in youth with osteogenesis imperfecta type I
    Pouliot-Laforte, A.
    Veilleux, L-N.
    Rauch, F.
    Lemay, M.
    JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2015, 15 (02) : 171 - 176
  • [45] Long-term follow-up in osteogenesis imperfecta type VI
    Trejo, P.
    Palomo, T.
    Montpetit, K.
    Fassier, F.
    Sato, A.
    Glorieux, F. H.
    Rauch, F.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (10) : 2975 - 2983
  • [46] Long-term follow-up in osteogenesis imperfecta type VI
    P. Trejo
    T. Palomo
    K. Montpetit
    F. Fassier
    A. Sato
    F. H. Glorieux
    F. Rauch
    Osteoporosis International, 2017, 28 : 2975 - 2983
  • [47] The functional muscle-bone unit in patients with osteogenesis imperfecta type I
    Veilleux, Louis-Nicolas
    Pouliot-Laforte, Annie
    Lemay, Martin
    Cheung, Moira S.
    Glorieux, Francis H.
    Rauch, Frank
    BONE, 2015, 79 : 52 - 57
  • [48] Osteogenesis Imperfecta Type VI in Individuals from Northern Canada
    Ward, Leanne
    Bardai, Ghalib
    Moffatt, Pierre
    Al-Jallad, Hadil
    Trejo, Pamela
    Glorieux, Francis H.
    Rauch, Frank
    CALCIFIED TISSUE INTERNATIONAL, 2016, 98 (06) : 566 - 572
  • [49] Osteogenesis Imperfecta Type VI in Individuals from Northern Canada
    Leanne Ward
    Ghalib Bardai
    Pierre Moffatt
    Hadil Al-Jallad
    Pamela Trejo
    Francis H Glorieux
    Frank Rauch
    Calcified Tissue International, 2016, 98 : 566 - 572
  • [50] Response to zolendronic acid in children with type III osteogenesis imperfecta
    Inusha Panigrahi
    Rashmi Ranjan Das
    Sheetal Sharda
    Ram Kumar Marwaha
    Niranjan Khandelwal
    Journal of Bone and Mineral Metabolism, 2010, 28 : 451 - 455